Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
E. M. W. van de Garde, H. Endeman, V. H. M. Deneer, D. H. Biesma, F. A. Sayed-Tabatabaei, H. J. T. Ruven, H. G. M. Leufkens, J. M. M. van den Bosch (Nieuwegein, Utrecht, The Hague, Netherlands). Angiotensin-converting enzyme insertion/deletion polymorphism and risk and outcome of pneumonia. Eur Respir J 2007; 30: Suppl. 51, 2920

Member's Comments

No comment yet.

Related content which might interest you: ACE I/D but not AGT (-6)A/G polymorphism is a risk factor for mortality in ARDS Source: Eur Respir J 2007; 29: 482-488 Year: 2007 Defining stability in pneumonia and the non-responding pneumonia Source: Annual Congress 2005 - Outcome in severe pneumonia Year: 2005 Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population Source: Eur Respir J 2006; 27: 1217-1222 Year: 2006 The influence of genetics on mortality from pneumonia Source: Annual Congress 2005 - Outcome in severe pneumonia Year: 2005 Management-based risk prediction in community-acquired pneumonia by scores and biomarkers Source: Eur Respir J 2013; 41: 974-984 Year: 2013 Genetic susceptibility to severe community-acquired pneumonia (CAP) in Buenos Aires Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia Source: Eur Respir J 2008; 31: 611-617 Year: 2008 Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia Year: 2007 Factors associated with unknown aetiology in patients with community-acquired pneumonia Source: Eur Respir J 2002; 20: 1254-1262 Year: 2002 Microbial evaluation of proton-pump inhibitors and the risk of pneumonia Source: Eur Respir J 2011; 38: 1165-1172 Year: 2011 Influence of chronic cardiovascular diseases (CVD) on course and outcome of community-acquired pneumonia (CAP) Source: International Congress 2017 – The acute patient: the clinical point-of-view Year: 2017 The risk of community-acquired pneumonia and the use of statins, ACE inhibitors and gastric acid suppressants Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis Year: 2008 COPD is associated with increased mortality in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: 346-351 Year: 2006 Validation of a computer predictive model to stratify risk and site of care in community acquired pneumonia (CAP) Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches Year: 2005 The association of angiotensin-converting enzyme gene insertion/deletion polymorphisms with OSA: a meta-analysis Source: Eur Respir J 2012; 40: 394-399 Year: 2012 Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor Source: Eur Respir J 2004; 24 : 779-785 Year: 2004 The predictive role of TLR4 +3725 G/C polymorphism in community-acquired pneumonia (CAP) severity course among young respondents with cytomegaloviral persistence (CMVP) Source: International Congress 2018 – Genetics in chronic pulmonary diseases Year: 2018 The role of ACE insertion/deletion polymorphism in RDS development in neonates from Russia Source: Eur Respir J 2005; 26: Suppl. 49, 393s Year: 2005 Angiotensin-converting enzyme insertion/deletion gene polymorphism and interstitial pulmonary fibrosis in Iranian population Source: Eur Respir J 2005; 26: Suppl. 49, 542s Year: 2005 Is it connection between systemic inflammation and risk of thrombotic disorders (by Padua scale) in hospitalized patients with community-acquired pneumonia (CAP)? Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018